Horizon Therapeutics Public Limited Company (HZNP) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Dublin, Ireland. The current CEO is Timothy P. Walbert.
HZNP has IPO date of 2011-07-28, 2,190 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $26.6B.
Horizon Therapeutics Public Limited Company is a biotechnology company focused on discovering, developing, and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. The company operates through two segments—Orphan and Inflammation—with a portfolio of 12 medicines spanning rare diseases, gout, ophthalmology, and inflammatory conditions. Its marketed products include TEPEZZA for thyroid eye disease, KRYSTEXXA for gout, RAVICTI and PROCYSBI for rare metabolic disorders, ACTIMMUNE for chronic granulomatous disease, and several anti-inflammatory and pain management therapies such as PENNSAID, DUEXIS, RAYOS, and VIMOVO. Founded in 2005 and headquartered in Dublin, Ireland, Horizon maintains research and commercial operations across multiple locations in the United States, Germany, and internationally through strategic collaborations with biotechnology partners.
